Imagine a world where prostate cancer could be detected earlier and more accurately, sparing millions of men from unnecessary, invasive procedures. That world just got a step closer to reality. Cleveland Diagnostics has achieved a groundbreaking milestone with the FDA approval of its IsoPSA® test, a revolutionary blood-based tool designed to transform prostate cancer diagnosis. But here's where it gets controversial: could this innovation significantly reduce the number of unnecessary biopsies, challenging the status quo of prostate cancer screening? Let's dive in.
Cleveland Diagnostics, a trailblazing precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for its IsoPSA® in vitro diagnostic (IVD) kit. This cutting-edge test is specifically designed to assist physicians in deciding whether a prostate biopsy is necessary for men aged 50 and older with elevated PSA levels. By focusing on prostate cancer-specific structural variants of the PSA protein, IsoPSA offers a more precise risk assessment, potentially reducing the diagnostic uncertainty that often leads to unnecessary procedures.
“FDA approval of our IsoPSA kit marks a significant milestone in Cleveland Diagnostics’ mission to help physicians and patients detect cancer early, when it’s most treatable,” said Arnon Chait, PhD, President and CEO of Cleveland Diagnostics. “We’re committed to expanding access to IsoPSA, ensuring more patients nationwide can benefit from this advanced diagnostic tool.”
The FDA’s decision was supported by robust clinical evidence from a large-scale, prospective study conducted across 14 U.S. sites, along with data from analytical validation studies. Prostate cancer is the second most prevalent cancer among American men, with 1 in 8 diagnosed in their lifetime. Annually, over 1 million men undergo prostate biopsies, yet up to 75% of these procedures fail to detect high-grade cancer. This diagnostic gap not only exposes patients to physical risks and emotional stress but also burdens the healthcare system with significant costs. IsoPSA aims to bridge this gap by providing clinicians and patients with a more accurate tool for risk assessment and biopsy decision-making.
“As a urologist, I’ve witnessed firsthand how the limitations of traditional PSA testing can lead to unnecessary anxiety and procedures for patients,” noted Dr. Aaron Berger, Chief Medical Officer at Associated Urological Specialists in Chicago. “IsoPSA is a game-changer, offering physicians a more reliable tool to assess risk and make informed biopsy decisions with greater confidence.”
Dr. Eric Klein, Emeritus Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Distinguished Scientist at GRAIL, Inc., emphasized the test’s clinical value: “The FDA’s approval highlights IsoPSA’s ability to distinguish between benign PSA elevations and those indicative of high-grade cancer. This achievement is the culmination of a decade of rigorous research and development.” Dr. Klein is a shareholder in Cleveland Diagnostics, Inc.
At the heart of IsoPSA is Cleveland Diagnostics’ proprietary IsoClear™ platform, which analyzes protein biomarkers at a structural level in the blood to provide actionable insights into disease states. Since 2020, IsoPSA has been available as a Laboratory-Developed Test (LDT), and it is now covered by Medicare and an increasing number of commercial payers. The test has also been incorporated into leading clinical practice guidelines, including the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection Guideline (2025) and the American Urology Association/Society of Urologic Oncology Guideline (2023).
And this is the part most people miss: While IsoPSA represents a significant advancement, it also raises questions about the future of prostate cancer screening. Will traditional PSA tests become obsolete? How will healthcare systems adapt to this new diagnostic landscape? These are critical questions that warrant further discussion.
Cleveland Diagnostics is dedicated to reshaping cancer detection through its innovative IsoClear™ platform, which harnesses the diagnostic potential of protein structure. By enabling novel, cancer-specific assessments within clinical lab settings, the company is paving the way for more accurate and patient-friendly diagnostics.
To learn more, visit ClevelandDx.com or IsoPSA.com.
What’s your take? Do you think IsoPSA will revolutionize prostate cancer screening, or are there potential drawbacks to this approach? Share your thoughts in the comments below!
